High SLC20A1 Expression Is Associated With Poor Prognosis for Radiotherapy of Estrogen Receptor-positive Breast Cancer.

Abstract

BACKGROUND/AIM:

Radiotherapy is one of the main treatments for estrogen receptor-positive (ER+) breast cancer. However, in some ER+ breast cancer cases, radiotherapy is insufficient to inhibit progression and there is a lack of markers to predict radiotherapy insensitivity. Solute carrier family 20 member 1 (SLC20A1) is a sodium/inorganic phosphate symporter, which has been proposed to be a viable prognostic marker for luminal A and B types of ER+ breast cancer. The present study examined the possibility of SLC20A1 as a novel biomarker for the prediction of radiotherapy efficiency.

PATIENTS AND METHODS:

The Molecular Taxonomy of Breast Cancer International Consortium dataset was downloaded from cBioportal and the prognosis of patients with high SLC20A1 expression (SLC20A1 high ) was compared with that of patients with low SLC20A1 expression, without or with radiotherapy and tumor stages I, II, and III, using the Kaplan-Meier method and multivariate Cox regression analyses of disease-specific and relapse-free survival.

RESULTS:

Patients in the SLC20A1 high group with radiotherapy showed poor clinical outcomes in both luminal A and luminal B breast cancers. Furthermore, in luminal A breast cancer at tumor stage I, patients in the SLC20A1 high  group with radiotherapy also showed poor clinical outcomes. Therefore, these results suggest that radiotherapy is insufficient for patients in the SLC20A1 high group for both luminal A and B types, and especially for the luminal A type at tumor stage I.

CONCLUSION:

SLC20A1 can be used as a prognostic marker for the prediction of the efficacy of radiotherapy for luminal A and luminal B breast cancers.

• Authors: Chotaro Onaga, Shoma Tamori, Izumi Matsuoka, Ayaka Ozaki, Hitomi Motomura, Yuka Nagashima, Tsugumichi Sato, Keiko Sato, Kouji Tahata, Yuyun Xiong, Yoshio Nakano, Yasunari Mano, Satoru Miyazaki, Kazunori Sasaki, Shigeo Ohno, Kazunori Akimoto
• Journal: Cancer diagnosis & prognosis (Cancer Diagn Progn) 2022 Jul-Aug Vol. 2 Issue 4 Pg. 429-442 ISSN: 2732-7787 [Electronic] Greece
• PMID: 35813014 (Publication Type: Journal Article)
• Copyright: Copyright 2022, International Institute of Anticancer Research.